Literature DB >> 14644972

Lassa fever: epidemiology, clinical features, and social consequences.

J Kay Richmond1, Deborah J Baglole.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14644972      PMCID： PMC286250          DOI： 10.1136/bmj.327.7426.1271

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  21 in total

1.  Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: evidence for viral cause.

Authors:  B S Liao; F M Byl; K K Adour
Journal:  Otolaryngol Head Neck Surg       Date:  1992-03       Impact factor: 3.497

2.  Clinical virology of Lassa fever in hospitalized patients.

Authors:  K M Johnson; J B McCormick; P A Webb; E S Smith; L H Elliott; I J King
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

3.  A case-control study of the clinical diagnosis and course of Lassa fever.

Authors:  J B McCormick; I J King; P A Webb; K M Johnson; R O'Sullivan; E S Smith; S Trippel; T C Tong
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

4.  Viral hemorrhagic fever antibodies in Nigerian populations.

Authors:  O Tomori; A Fabiyi; A Sorungbe; A Smith; J B McCormick
Journal:  Am J Trop Med Hyg       Date:  1988-03       Impact factor: 2.345

5.  Acute sensorineural deafness in Lassa fever.

Authors:  D Cummins; J B McCormick; D Bennett; J A Samba; B Farrar; S J Machin; S P Fisher-Hoch
Journal:  JAMA       Date:  1990 Oct 24-31       Impact factor: 56.272

6.  Hematologic dysfunction in Lassa fever.

Authors:  S Fisher-Hoch; J B McCormick; D Sasso; R B Craven
Journal:  J Med Virol       Date:  1988-10       Impact factor: 2.327

7.  A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy.

Authors:  M E Price; S P Fisher-Hoch; R B Craven; J B McCormick
Journal:  BMJ       Date:  1988-09-03

8.  Lassa fever. Effective therapy with ribavirin.

Authors:  J B McCormick; I J King; P A Webb; C L Scribner; R B Craven; K M Johnson; L H Elliott; R Belmont-Williams
Journal:  N Engl J Med       Date:  1986-01-02       Impact factor: 91.245

9.  A prospective study of the epidemiology and ecology of Lassa fever.

Authors:  J B McCormick; P A Webb; J W Krebs; K M Johnson; E S Smith
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

10.  A plasma inhibitor of platelet aggregation in patients with Lassa fever.

Authors:  D Cummins; S P Fisher-Hoch; K J Walshe; I J Mackie; J B McCormick; D Bennett; G Perez; B Farrar; S J Machin
Journal:  Br J Haematol       Date:  1989-08       Impact factor: 6.998
View more
  121 in total

Review 1.  Laboratory Diagnosis of Lassa Fever.

Authors:  Vanessa Raabe; Jeffrey Koehler
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

2.  Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates.

Authors:  Igor S Lukashevich; Ricardo Carrion; Maria S Salvato; Keith Mansfield; Kathleen Brasky; Juan Zapata; Cristiana Cairo; Marco Goicochea; Gia E Hoosien; Anysha Ticer; Joseph Bryant; Harry Davis; Rasha Hammamieh; Maria Mayda; Marti Jett; Jean Patterson
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

3.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

4.  Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.

Authors:  Vincent Madelain; Jérémie Guedj; France Mentré; Thi Huyen Tram Nguyen; Frédéric Jacquot; Lisa Oestereich; Takumi Kadota; Koichi Yamada; Anne-Marie Taburet; Xavier de Lamballerie; Hervé Raoul
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

5.  Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice.

Authors:  Masaharu Iwasaki; Cherie T Ng; Beatrice Cubitt; Juan C de la Torre
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

6.  A Highly Conserved Leucine in Mammarenavirus Matrix Z Protein Is Required for Z Interaction with the Virus L Polymerase and Z Stability in Cells Harboring an Active Viral Ribonucleoprotein.

Authors:  Masaharu Iwasaki; Juan C de la Torre
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 7.  VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.

Authors:  Pierre Leblanc; Leonard Moise; Cybelle Luza; Kanawat Chantaralawan; Lynchy Lezeau; Jianping Yuan; Mary Field; Daniel Richer; Christine Boyle; William D Martin; Jordan B Fishman; Eric A Berg; David Baker; Brandon Zeigler; Dale E Mais; William Taylor; Russell Coleman; H Shaw Warren; Jeffrey A Gelfand; Anne S De Groot; Timothy Brauns; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 8.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

9.  Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.

Authors:  Junki Maruyama; Elizabeth J Mateer; John T Manning; Rachel Sattler; Alexey V Seregin; Natalya Bukreyeva; Frank R Jones; Joseph P Balint; Elizabeth S Gabitzsch; Cheng Huang; Slobodan Paessler
Journal:  Vaccine       Date:  2019-09-24       Impact factor: 3.641

10.  The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses.

Authors:  Masaharu Iwasaki; Beatrice Cubitt; Brian M Sullivan; Juan C de la Torre
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.